1,377 Shares in Takeda Pharmaceutical Co Ltd (TAK) Purchased by Shine Investment Advisory Services Inc.

Shine Investment Advisory Services Inc. bought a new position in shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,377 shares of the company’s stock, valued at approximately $28,000.

Other large investors also recently modified their holdings of the company. Contravisory Investment Management Inc. purchased a new position in shares of Takeda Pharmaceutical during the first quarter worth approximately $28,000. First Hawaiian Bank purchased a new position in shares of Takeda Pharmaceutical during the first quarter worth approximately $35,000. Dubuque Bank & Trust Co. purchased a new position in shares of Takeda Pharmaceutical during the first quarter worth approximately $41,000. Edge Wealth Management LLC purchased a new position in shares of Takeda Pharmaceutical during the first quarter worth approximately $55,000. Finally, Vigilant Capital Management LLC purchased a new position in shares of Takeda Pharmaceutical during the first quarter worth approximately $63,000. 3.45% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE:TAK opened at $18.96 on Wednesday. The company has a market cap of $29.58 billion, a PE ratio of 17.72 and a beta of 0.73. Takeda Pharmaceutical Co Ltd has a one year low of $15.50 and a one year high of $23.95. The company has a debt-to-equity ratio of 1.19, a quick ratio of 2.81 and a current ratio of 3.06.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Friday, February 1st. The company reported $0.75 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a net margin of 6.13% and a return on equity of 14.62%. The firm had revenue of $4.43 billion for the quarter. Sell-side analysts anticipate that Takeda Pharmaceutical Co Ltd will post 0.47 earnings per share for the current year.

TAK has been the topic of a number of research reports. Goldman Sachs Group reaffirmed a “buy” rating on shares of Takeda Pharmaceutical in a research report on Tuesday, March 19th. Zacks Investment Research raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a research report on Wednesday, March 13th.

COPYRIGHT VIOLATION WARNING: “1,377 Shares in Takeda Pharmaceutical Co Ltd (TAK) Purchased by Shine Investment Advisory Services Inc.” was originally reported by PressOracle and is the property of of PressOracle. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://pressoracle.com/news/2019/04/17/1377-shares-in-takeda-pharmaceutical-co-ltd-tak-purchased-by-shine-investment-advisory-services-inc.html.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Further Reading: What is the Gross Domestic Product (GDP)?

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.